Market Newsdesk

TORONTO and NEW YORK, Nov. 24, 2020 (GLOBE NEWSWIRE) — Uber announced today the introduction of Uber Direct, a new and operationally efficient way for Canadian retailers to manage their delivery process, reach their customers, and quickly deliver right to their doorstep—without contact. Ahead of the holiday season, a much-needed evolution of e-commerce and fulfillment, Uber is also pleased to announce its collaboration with Bond Brand Loyalty, Inc. to bring a new purchase and redemption experience to brands and their clients’ millions of reward program members.

The transformative solution that leverages Uber Direct’s technology allows retail e-commerce and loyalty program operators to meet customers’ rising expectations for fast and convenient delivery. Customers who make purchases or redeem loyalty points for rewards can have their items delivered within hours versus days via traditional delivery methods.

Uber Direct builds upon Uber Eats’ recent expansion into grocery and convenience-store delivery. Retailers and manufacturers can now leverage Uber’s technology as an operationally efficient way to move goods between locations and into the hands of customers. With the scale and reliability of Uber, Bond is setting a new standard of fulfillment and delivery, connecting the last mile of e-commerce with loyalty.

“With the pandemic, delivery has evolved from a luxury to a utility as businesses look for—and consumers expect—real-time fulfillment,” said Ronnie Gurion, General Manager, Uber for Business. “We’re pleased to partner with Bond Brand Loyalty to accelerate their delivery standard for loyalty point rewards from days to within hours.”

“Solving complex customer challenges in this new norm requires new approaches and innovative digital solutions that give consumers confidence that their items are assuredly en route, and a rewarding immediate gratification feeling,” said Sean Claessen, Chief Strategy Officer for Bond. “By combining Bond’s leading customer experience and loyalty thinking and platform with Uber’s best-in-class technology, we’re ushering in a new era of customer experience. This move is part of the next step in Bond’s broader customer-linking plans and we are exceedingly excited about the road ahead with Uber.”  

Research shows that consumers will form new brand loyalties based on availability and delivery speed. Nearly three-quarters (74%) of consumers surveyed said same-day delivery increased their brand loyalty. In addition, Bond’s Loyalty Report found that the top drivers of loyalty when it comes to redemption include ease of the redemption process and time it takes to receive redeemed rewards (a 6.8X satisfaction lift).

Consumers have prioritized convenience and immediacy for years, declaring in research that nearly a third of them are entirely willing to pay a premium for an increased level of service. And our pilot with Uber confirms the attitudinal data holds true in real life, with consumers demonstrating significantly higher satisfaction, two-fold (2X) promoters in NPS scoring, and an increased propensity to repeat a transaction like this again.

Having already worked to integrate Uber rides and eats into the rewards experience of several major bank credit card reward portfolios, popular consumer engagement programs, contests, and promotions, Bond is excited to bring a better experience to customers now in delivery and fulfilment of other items they’re after—with the scale, reliability, and convenience of Uber.

To learn more, read our latest blogpost A CX Game-Changer Puts Loyalty in The Fast Lane.

About Bond
Bond Brand Loyalty, Inc. solves complex customer challenges with a unique blend of human-centered design, data science, and loyalty mechanics that transforms how brands win, serve, and keep customers. Working globally with iconic brands, Bond designs, builds, and operates digital and human experiences that create measurable, authentic, and long-lasting relationships through a combination of solutions that includes customer experience design, loyalty consulting and management, CRM and digital marketing, research and analytics, channel and employee engagement, and program technology and platforms. For more information, visit bondbrandloyalty.com, follow Bond on LinkedIn and Twitter, or connect by phone at 1-844-277-2663.

About Uber

Uber’s mission is to create opportunity through movement. We started in 2010 to solve a simple problem: how do you get access to a ride at the touch of a button? More than 15 billion trips later, we’re building products to get people closer to where they want to be. By changing how people, food, and things move through cities, Uber is a platform that opens up the world to new possibilities.

For more information, please contact:

Richard Lane
Bond Brand Loyalty
[email protected]

Laura Miller 
Uber Canada
[email protected]

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/981924e0-5074-4898-ac03-18f03d7ad49c 

TORONTO and DENVER, Nov. 24, 2020 (GLOBE NEWSWIRE) — MJardin Group, Inc. (“MJardin” or the “Company”) (CSE: MJAR) (OTCQX: MJARF), a leader in premium cannabis production, announced today that as part of its ongoing review, evaluation and turnaround process, it has terminated certain management services agreements and consulting agreements (“MSAs”) with parties located in Denver, Colorado, effective immediately.

Following this announcement and the disclosure contained in the Company’s press release dated March 31, 2020, the Company will no longer have any active MSAs in Colorado.

The MSAs between the Company and 3B Ventures, LLC and TwoG Ventures, LLC, (together, the “Clients”) will be terminated, on the consent of the parties, effective immediately. The termination of the MSAs with the Clients will not affect the promissory notes, intellectual property agreements and lease obligations currently in place between the Clients and MJardin.

Termination of the MSAs will substantially reduce U.S. segment revenues and ongoing management obligations, thus reducing costs, which will place fewer cash flow demands on MJardin. The Company remains committed to exploring growth opportunities in the Colorado market while maintaining strict discipline in its approach to capital deployment.

About MJardin Group

MJardin Group’s mission is to set the standard for successful ownership of assets in the cannabis industry. Our founders spent a decade refining cultivation methodology, collecting and implementing data driven standards and designing state of the art facilities. Today, MJardin owns multiple operations in Canada, supplying the market with premium products. We are committed to our Canadian First Nation joint ventures and all our strategic partnerships across the cannabis supply chain. MJardin is publicly listed on the CSE (MJAR) and the QXOTC (MJARF) with offices in Toronto, Ontario and Denver, Colorado.

The CSE has not in any way passed upon the merits of and has neither approved nor disapproved the contents of this news release.

This news release does not constitute an offer to sell or a solicitation of an offer to sell any of the securities in the United States. The securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”) or any state securities laws and may not be offered or sold within the United States or to U.S. Persons unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is available.

Forward-Looking Information

This press release contains “forward-looking information” within the meaning of applicable Canadian securities legislation and may also contain statements that may constitute “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Such forward-looking information and forward-looking statements are not representative of historical facts or information or current condition, but instead represent only the Company’s beliefs regarding future events, plans or objectives, many of which, by their nature, are inherently uncertain and outside of the Company’s control. Generally, such forward-looking information or forward-looking statements can be identified by the use of forward-looking terminology such as, ‘may’, ‘will’, ‘should’, ‘could’, ‘would’, ‘expects’, ‘intends’, ‘plans’, ‘anticipates’, ‘believes’, ‘estimates’, ‘projects’, ‘predicts’, ‘potential’, ‘outlook’ or ‘continue’ or the negative of those forms or other comparable terms. Statements about, among other things, future developments in the business and operations of MJardin, contain forward-looking information. These statements should not be read as guarantees of future performance or results. The Company’s forward-looking information and forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the Company’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking information and forward-looking statements, including but not limited to: our ability to identify and pursue growth, financing and other strategic objectives, and the regulatory and economic environments in the jurisdictions we operate or intend to operate or invest in. Reference should also be made to the risks and uncertainties which are discussed in greater detail in the “Risk Factors” section of the Company’s Annual Management’s Discussion and Analysis filed on SEDAR and as described from time to time in documents filed by the Company with Canadian securities regulatory authorities. Readers are cautioned that the foregoing list of factors is not exhaustive. Although such statements are based on management’s reasonable assumptions at the date such statements are made, there can be no assurance that any proposed transactions will occur or that such forward-looking information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such forward-looking information and forward-looking statements. Accordingly, readers should not place undue reliance on the forward-looking information and forward-looking statements. No assurances are given as to the future trading price or trading volumes of MJardin’s shares, nor as to the Company’s financial performance in future financial periods. The Company does not intend to update any of these factors or to publicly announce the result of any revisions to any of the Company’s forward-looking information and forward-looking statements contained herein, whether as a result of new information, any future event or otherwise. Except as otherwise indicated, this press release speaks as of the date hereof. The distribution of this press release does not imply that there has been no change in the affairs of the Company after the date hereof or create any duty or commitment to update or supplement any information provided in this press release or otherwise. MJardin assumes no responsibility to update or revise forward-looking information and forward-looking statements to reflect new events or circumstances unless required by applicable law.

Caution Regarding Cannabis Operations in the United States

Investors should note that there are significant legal restrictions and regulations that govern the cannabis industry in the United States. Cannabis remains a Schedule I drug under the US Controlled Substances Act, making it illegal under federal law in the United States to, among other things, cultivate, distribute or possess cannabis in the United States. Financial transactions involving proceeds generated by, or intended to promote, cannabis-related business activities in the United States may form the basis for prosecution under applicable US federal money laundering legislation.

While the approach to enforcement of such laws by the federal government in the United States has trended toward non-enforcement against individuals and businesses that comply with medical or adult-use cannabis programs in states where such programs are legal, strict compliance with state laws with respect to cannabis will neither absolve the Company of liability under US federal law, nor will it provide a defense to any federal proceeding which may be brought against the Company. The enforcement of federal laws in the United States is a significant risk to the business of the Company and any proceedings brought against the Company thereunder may adversely affect the Company’s operations and financial performance.

INVESTOR CONTACT:
Ali Mahdavi		Pat Witcher
Capital Markets & Investor Relations		Chief Executive Officer
416-962-3300		720-613-4019
[email protected]

 

• One of the industry’s first “one-box” EyeQ5 front-facing camera systems
• Magna’s electronics and camera expertise, Mobileye’s image-processing technology
• Magna ADAS systems are found on more than 250 vehicle models on the road today

TROY, Mich., Nov. 24, 2020 (GLOBE NEWSWIRE) — A premium automaker in Europe will soon be able to offer industry-leading driver assistance features across a larger portion of its vehicle lineup, thanks to the next generation of camera-based driver assistance from Magna.

The Magna Gen5 “one-box” solution is a Mobileye EyeQ5-based system – one of the industry’s first where the forward-facing camera and related software are contained in a single assembly. Benefits include lower cost, simplified installation on the assembly line, and the ability for the technology to be applied to a wider range of an automaker’s lineup. The system will provide drivers with safety and convenience features such as adaptive cruise control, automatic emergency braking and pedestrian detection. 

As with previous generations, the system combines Magna’s electronics and camera expertise with Mobileye’s system-on-chip (SoC) image-processing technology. The camera features a 120-degree, 8-megapixel optical path, while Magna has continued to refine its world-class camera manufacturing processes to achieve the quality and volumes required of global vehicle platforms. Mobileye collaborated with Magna engineers to ensure that the EyeQ5 met and exceeded new requirements related to the launch program.

“At Magna, our ADAS capability has been built on automotive cameras, evidenced by more than 500 U.S. patents in the last 15 years,” said Uwe Geissinger, President of Magna Electronics. “As demonstrated by our long collaboration with Mobileye and the introduction of our new Gen5 system, we’re constantly working to deliver innovative systems to our customers and help make vehicles safer and more enjoyable to drive.”

“We have been working with Magna on camera-based ADAS since 2007, and our collaboration continues to provide leading-edge driver-assistance features,” said Erez Dagan, Executive Vice President for Products and Strategy at Mobileye. “This latest system represents a new level of performance and functionality, and we’re already looking for ways to make subsequent generations even better.”

Magna provides global automakers with ADAS technologies – including the PACE Award-winning Trailer Angle Detection, Automatic Emergency Braking, and rearview object and pedestrian detection – to more than 250 vehicle models on the road today.

TAGS
Automotive camera systems, camera-based ADAS, automotive electronics

INVESTOR CONTACT
Louis Tonelli, Vice President, Investor Relations
[email protected], (+1) 905.726.7035

MEDIA CONTACT
Tracy Fuerst, Vice President, Corporate Communications & PR
[email protected], (+1) 248.631.7004

ABOUT MAGNA
We are a mobility technology company. We have over 157,000 entrepreneurial-minded employees, 344 manufacturing operations and 93 product development, engineering and sales centres in 27 countries. We have complete vehicle engineering and contract manufacturing expertise, as well as product capabilities that include body, chassis, exteriors, seating, powertrain, active driver assistance, electronics, mechatronics, mirrors, lighting and roof systems. Our common shares trade on the Toronto Stock Exchange (MG) and the New York Stock Exchange (MGA). For further information about Magna, visit www.magna.com.

THIS RELEASE MAY CONTAIN STATEMENTS WHICH CONSTITUTE “FORWARD-LOOKING STATEMENTS” UNDER APPLICABLE SECURITIES LEGISLATION AND ARE SUBJECT TO, AND EXPRESSLY QUALIFIED BY, THE CAUTIONARY DISCLAIMERS THAT ARE SET OUT IN MAGNA’S REGULATORY FILINGS. PLEASE REFER TO MAGNA’S MOST CURRENT MANAGEMENT’S DISCUSSION AND ANALYSIS OF RESULTS OF OPERATIONS AND FINANCIAL POSITION, ANNUAL INFORMATION FORM AND ANNUAL REPORT ON FORM 40-F, AS REPLACED OR UPDATED BY ANY OF MAGNA’S SUBSEQUENT REGULATORY FILINGS, WHICH SET OUT THE CAUTIONARY DISCLAIMERS, INCLUDING THE RISK FACTORS THAT COULD CAUSE ACTUAL EVENTS TO DIFFER MATERIALLY FROM THOSE INDICATED BY SUCH FORWARD-LOOKING STATEMENTS. THESE DOCUMENTS ARE AVAILABLE FOR REVIEW ON MAGNA’S WEBSITE AT 

WWW.MAGNA.COM

.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/cf925241-95aa-4512-be68-d2071c01bcb3

WAYNE, N.J., Nov. 24, 2020 (GLOBE NEWSWIRE) — Konica Minolta Healthcare Americas, Inc. announces that Centro Rossi, a leading healthcare provider in Argentina with 13 locations throughout Greater Buenos Aires, is implementing the Exa® Enterprise Imaging Platform throughout all of its centers. Konica Minolta also announced an agreement with Habitat Evolution to distribute the Exa Enterprise Imaging Platform within all regions of Argentina.

Founded by Dr. Enrique Martín Rossi in 1980, Centro Rossi has led the modernization of diagnostic imaging services and elevated the quality of care in Argentina by acquiring state-of-the-art systems and retaining highly trained staff. The organization selected the Exa Platform because it is customizable and adaptable to the specific needs of the region. Konica Minolta and Centro Rossi will collaborate to continue enhancing and evolving the Exa Platform for the Latin American market.

“At Centro Rossi, we consistently seek the best solutions to provide our patients with the highest standard of care,” says Santiago Enrique Rossi, MD, Medical Director at Centro Rossi. “The Exa Enterprise Imaging Platform will help us provide better care for our patients and referring physicians and we are very proud to work with Konica Minolta to further innovate and bring new imaging informatics solutions to the Latin American healthcare market.

The Exa Platform is designed to allow for the rapid adoption of new technologies and capabilities as customer and market needs evolve. With a web-based, Zero-Footprint platform, the Exa Platform uses Server-Side Rendering to facilitate the fast transfer of large imaging studies regardless of the internet connection. The diagnostic-quality Zero Footprint viewer provides access to patient data from any device and from any location with an internet connection. As a leader in the region, Centro Rossi is uniquely positioned to provide insights on the strategic direction of Healthcare IT in Latin America.

“As we introduce Konica Minolta’s Healthcare IT solutions to the region, this partnership provides new opportunities to innovate our Exa Enterprise Imaging Platform and introduce new technologies to meet the unique and evolving needs of the local market. Centro Rossi’s patient-centric business model aligns with ours and we are very excited to enter into this strategic partnership with one of the most prestigious imaging center organizations in Latin America,” says Antonio Uzcátegui, Director of Health Technology for Latin America at Konica Minolta Healthcare Americas, Inc.

Regarding the partnership with Habitat Evolution, Daniela Prosperi, Director of Operations for Habitat Evolution, says signing a distribution agreement with a multinational company like Konica Minolta Healthcare underscores the importance of developing markets even in the midst of a difficult business climate. “It’s all about innovation, and this is only the first step of many to come with this collaboration,” adds Prosperi. “The Habitat Evolution team is proud and committed to make this partnership a complete success.”

Ernesto Márquez, General Manager of the Latin American Region for Konica Minolta Healthcare, expressed his enthusiasm for the new distributor partnership. “Habitat Evolution’s experienced professionals are uniquely qualified to collaborate with our organization to further develop our Healthcare IT business footprint in Argentina.”

About Konica Minolta Healthcare Americas, Inc.

Konica Minolta Healthcare is a world-class provider and market leader in medical diagnostic imaging and healthcare information technology. With over 75 years of endless innovation, Konica Minolta is globally recognized as a leader providing cutting-edge technologies and comprehensive support aimed at providing real solutions to meet customer’s needs and helping make better decisions sooner. Konica Minolta Healthcare Americas, Inc., headquartered in Wayne, NJ, is a unit of Konica Minolta, Inc. (TSE:4902). For more information on Konica Minolta Healthcare Americas, Inc., please visit www.konicaminolta.com/medicalusa.

Contact: 
Mary Beth Massat                                                        
Massat Media
224.578.2388
www.konicaminolta.com/medicalusa

VANCOUVER, British Columbia, Nov. 24, 2020 (GLOBE NEWSWIRE) — Cypress Development Corp. (TSX-V:CYP) (OTCQB:CYDVF) (Frankfurt:C1Z1) (“Cypress” or “the Company”) reports the completion of additional metallurgical testing following the positive Prefeasibility Study (PFS) published on the Company’s 100%-owned Clayton Valley Lithium Project in Nevada, USA. The testing was conducted at Continental Metallurgical Services in Montana and NORAM Engineering in British Columbia, in preparation for the Company’s pilot plant program as outlined in the PFS.

Highlights

• Testing resulted in 80.2% extraction of lithium when a sodium chloride solution was used instead of distilled water in leaching claystone under Cypress’ sulfuric acid leach process.
• Lithium in the resulting leach solution was successfully concentrated at levels comparable to the PFS with limited interference by chlorides and other minerals present.
• The ability to tolerate high chloride levels in the process is significant because it allows the consideration of a wider range of resources for water supply including geothermal solutions and lithium-bearing brine.
• An alternate approach was tested using hydrochloric acid instead of sulfuric acid in leaching the claystone. A lithium extraction of 85.3% was obtained, suggesting hydrochloric acid may be a more effective reagent if high chloride levels are present in the water used in leaching.

“The test results are significant and demonstrate the Cypress process will work with high saline water sources,” said Cypress CEO Bill Willoughby.

“The observation that leaching clay is more efficient when using hydrochloric acid with a saline brine is intriguing as it suggests a way to eliminate sulfuric acid from the process. This would benefit the project by eliminating the purchasing and transportation of sulfur which are limiting constraints on increasing the scale of production. Further work, however, is needed.” The Company is conducting additional tests and analyses to determine if there is an alternate process that could be tested in parallel with the pilot plant program.

“We continue working toward the next stage of development with the pilot plant program,” said Bill Willoughby. “Our objective remains to initiate the program and work to advance the project to a full feasibility study. We have now shown we have a lithium deposit and an extraction process which are compatible with high saline water sources.”

Qualified Person:

Todd Fayram, MMSA-QP, is the qualified person as defined by National Instrument 43-101 and has approved the technical information in this release.

About Cypress Development Corp.:

Cypress Development Corp. is a publicly traded exploration company focused on developing the Company’s 100%-owned Clayton Valley Lithium Project in Nevada. Exploration and development by Cypress discovered a world-class resource of lithium-bearing claystone adjacent to the Albemarle Silver Peak mine, North America’s only lithium brine operation. The size of the resource makes the Clayton Valley Project a premier source that has the potential to impact the supply of lithium for the fast-growing global energy storage battery market.

Clayton Valley Lithium Project, Nevada claims map:

https://www.cypressdevelopmentcorp.com/site/assets/files/3573/cyp_cm_series_drill_hole_map_2020.jpg

Cypress Development Corp. has approximately 98.4 million shares issued and outstanding.

To find out more about Cypress Development Corp. (TSX-V: CYP), visit our website at www.cypressdevelopmentcorp.com.

CYPRESS DEVELOPMENT CORP.

“
Dr. Bill Willoughby
”

                                        
WILLIAM WILLOUGHBY, PhD., PE
Chief Executive Officer

For further information contact myself or:
Don Myers
Cypress Development Corp.
Director, Corporate Communications
Telephone: 604-639-3851
Toll Free: 800-567-8181
Facsimile: 604-687-3119
Email: [email protected]

NEITHER THE TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THE CONTENT OF THIS NEWS RELEASE.

This release includes certain statements that may be deemed to be “forward-looking statements”. All statements in this release, other than statements of historical facts, that address events or developments that management of the Company expects, are forward-looking statements. Although management believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance, and actual results or developments may differ materially from those in the forward-looking statements. The Company undertakes no obligation to update these forward-looking statements if management’s beliefs, estimates or opinions, or other factors, should change. Factors that could cause actual results to differ materially from those in forward-looking statements, include market prices, exploration and development successes, continued availability of capital and financing, and general economic, market or business conditions. Please see the public filings of the Company at www.sedar.com for further information.

• MDSAP is the highest quality and regulatory
  standard
  in the medical device industry 

TORONTO, Nov. 24, 2020 (GLOBE NEWSWIRE) — Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late stage theranostic company advancing therapeutic options for sepsis and septic shock, as well as commercializing a new proprietary platform targeting the renal replacement therapy market, today announced that its wholly owned subsidiary, Dialco Medical Inc. (“Dialco”) received its Medical Device Single Audit Program (“MDSAP”) certification for “the design, manufacture, installation and service of equipment for extracorporeal blood purification and its related disposable” under ISO 13485 for Canada (Medical Devices Regulations – Part 1- SOR 98/282) and United States (21 CFR 820, 21 CFR 803, 21 CFR 806, 21 CFR 807 (Subparts A to D), 21 CFR 821).

MDSAP allows the conduct of a single regulatory audit of a medical device manufacturers quality management system to satisfy the requirements of multiple regulatory jurisdictions or authorities to enable appropriate regulatory oversight of medical device manufacturers’ quality management systems while minimizing regulatory burden on the industry. The program was developed by the International Medical Device Regulators Forum and currently representatives from The Therapeutic Goods Administration in Australia; Brazil’s Agência Nacional de Vigilância Sanitária; Health Canada Canadian Medical Device Regulations; Japan’s Ministry of Health, Labour and Welfare and Pharmaceutical and Medical Devices Agency, and the U.S. Food and Drug Administration, Center for Devices and Radiological Health participate in the program.

“On Dialco’s continued commercialization path, MDSAP and ISO 13485 certifications represent important milestones. Not only does certification through these programs validate our ongoing commitment to maintaining the highest quality assurance standards within the medical device industry, but MDSAP certification is also a Health Canada mandated requirement to sell medical devices in Canada,” said Dr. Gualtiero Guadagni, President of Dialco. “Additionally, Dialco’s receipt of its own MDSAP certification supports Dialco’s continuous pathway of achieving a fully independent operating structure.”

About Spectral
and
Dialco

Spectral is a Phase III company seeking U.S. FDA approval for its unique product for the treatment of patients with septic shock, Toraymyxin™ (“PMX”). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Company’s Endotoxin Activity Assay (EAA™), the only FDA cleared diagnostic for the risk of developing sepsis.

PMX is approved for therapeutic use in Japan and Europe, and has been used safely and effectively on more than 200,000 patients to date. In March 2009, Spectral obtained the exclusive development and commercial rights in the U.S. for PMX, and in November 2010, signed an exclusive distribution agreement for this product in Canada. Approximately 330,000 patients are diagnosed with severe sepsis and septic shock in North America each year.

Spectral, through its wholly owned subsidiary, Dialco Medical Inc. (“Dialco”), is also commercializing a new proprietary platform, “SAMI”, targeting the renal replacement therapy (“RRT”) market. Dialco is also seeking regulatory approval for in-home use of “DIMI” which is based on the same RRT platform, but will be intended for home hemodialysis use. “DIMI” recently received its FDA 510k clearance for use in hospital and clinical settings.

Spectral is listed on the Toronto Stock Exchange under the symbol EDT. For more information, please visit www.spectraldx.com.

Forward-looking statement

Information
in
this
news
release
that
is
not
current
or
historical
factual
information
may
constitute
forward-looking information
or forward looking statements
within the meaning of securities laws. Implicit in this information, particularly in respect of the
future outlook
of Spectral and anticipated events or results, are assumptions based on beliefs of
Spectral’s
senior management
as
well
as
information
currently
available
to
it.
While
these
assumptions
were
considered
reasonable by Spectral at the time of preparation, they may prove to be incorrect.
Readers are cautioned that actual results are
subject
to
a
number
of
risks
and
uncertainties,
including
the
availability
of
funds
and
resources
to
pursue
R&D projects, the successful and timely completion of clinical studies, the ability of Spectral to take advantage of business opportunities in the biomedical industry, the granting of necessary approvals by regulatory authorities
including but not limited to the ongoing impact of COVID-19.
Actual results could differ materially from what is currently expected, and readers
are cautioned
not to place undue reliance on these forward-looking statements. Except as required by law, the Company disclaims any obligation to update or revise any forward-looking statements. Reference is also made to the other risks and uncertainties that may affect the
Company which
are more fully described in
Spectral’s
Annual Information Form dated March 26, 2020 and other filings of Spectral with the securities regulatory authorities which are available at www.sedar.com.

The TSX has not reviewed and does not accept responsibility for the adequacy or accuracy of this statement.

For further information, please contact:

Dr. Paul Walker President and CEO Spectral Medical Inc. 416-626-3233 ext. 2100 [email protected]

Mr. Chris Seto COO & CFO Spectral Medical Inc. 416-626-3233 ext. 2004 [email protected]

Ali Mahdavi Capital Markets & Investor Relations 416-962-3300 [email protected]

LARGO, FL, Nov. 24, 2020 (GLOBE NEWSWIRE) — via NewMediaWire — Today, Leone Asset Management (OTC PINK: LEON) Subsidiary Go Epic Health, Inc., announced that they have entered into an International Distribution Agreement with Canavation Product Group, Inc.

The distribution agreement will begin with Go Epic Health’s Flagship product Cholesterade®.  Canavation Product Group will be handling all aspects of manufacturing, marketing and distribution of Cholesterade® throughout the United Kingdom and the European Union. 

James Price, Chairman and CEO of Leone Asset, stated, “We have been very patient with finding the correct partner to handle distribution of Cholesterade® in International Markets. We are extremely pleased to have entered into this agreement with Canavation.  The company as well as management have a deep history and knowledge of distributing consumer products throughout the EU and the UK and we anticipate a very long and mutually profitable relationship.”

About Leone Asset Management 

Leone Asset Management, Inc., is a multi-national, multi-industry conglomerate with subsidiary companies that operate in Health and Wellness, Media & Communications, Infrastructure development, agriculture management and mining exploration. For additional information, please visit www.leoneasset.com. 

About Canavation Product Group

Canavation is an award-winning group of wellness companies and joint ventures that include an international product development arm, cGMP nutraceutical manufacturing facilities and a multinational sales and distribution pipeline.  We develop a broad range of highly differentiated consumer products leveraging rare ingredients and delivery systems.  This includes a patent-protected cannabinoid technology offering 18x higher bioavailability and catalog of future rare cannabinoids.  For additional information, please visit www.canavation.com

Forward-Looking Statements Disclosure:

This press release may contain “forward-looking statements” within the meaning of the federal securities laws. In this context, forward-looking statements may address the Company’s expected future business and financial performance, and often contain words such as “anticipates,” “beliefs,” “estimates,” “expects,” “intends,” ” plans,” “seeks,” “will,” and other terms with similar meaning. These forward-looking statements by their nature address matter that are, to different degrees, uncertain. Although the Company believes that the assumptions upon which its forward-looking statements based are reasonable, it can provide no assurances that these assumptions will prove to be correct. All forward-looking statements in this press release are expressly qualified by such cautionary statements, risk, and uncertainties, and by reference to the underlying assumptions.

Contact:

James Price

[email protected]

727-581-1500

NEWPORT BEACH, Calif., Nov. 24, 2020 (GLOBE NEWSWIRE) — Collectors Universe, Inc. (“Collectors”” or the “Company”) (NASDAQ: CLCT), a leading provider of value-added authentication and grading services to dealers and collectors of collectibles, is reminding its stockholders that the Company’s 2020 Annual Stockholders Meeting, to be held on Thursday, December 10, 2020, at 10:00 a.m. (Pacific Time), will be a virtual meeting that will be conducted exclusively via a live audio webcast. The decision to hold a virtual-only Annual Meeting was prompted by the public health impact of the coronavirus pandemic and to support the health and safety of the Company’s stockholders, employees and communities.

Stockholders of record as of the close of business on October 13, 2020 can join the meeting via the Internet at www.virtualshareholdermeeting.com/CLCT2020 by using the 16-digit control number included on the proxy card, voting instruction form, or notice previously received. Any stockholder that holds its shares through a bank or broker or other nominee holder, and does not have a control number, should contact the bank, broker or other nominee holder to obtain that number. Stockholders are encouraged to log in to the website by 9:45 a.m. (Pacific Time) on the day of the Annual Meeting to access and review meeting materials. Stockholders will be able to submit their questions through the meeting website and vote their shares electronically during the Annual Meeting by following the instructions on the meeting website during the Annual Meeting. Access to the live webcast will also be made available on Collectors Universe’s Events and Presentations website page.

Other
Methods of
Vot
ing
at the Virtual Annual Meeting

Whether or not you plan to attend the virtual Annual Meeting, please do not wait until the date of the Annual Meeting to vote your shares. Instead, vote as soon as possible, by signing, dating and returning the proxy card or voting instruction card that you received in the postage-paid envelope provided, or use the telephone or Internet voting instructions that are on the Notice of Availability of Internet Proxy Materials mailed to you and on proxy card. If you hold your shares in an account at a bank, broker, dealer or other nominee, you will need to follow the instructions provided by your bank, broker, dealer or other nominee, to vote your shares. Voting your shares by any of the above methods will ensure that, if you are unable to “attend” the virtual Annual Meeting, your shares will be voted in accordance with your wishes. Voting now by one of these methods will not limit your right to change your vote later or to “attend” the virtual Annual Meeting.

If you have additional questions about the election of directors or the other proposals to be voted on at the Annual Meeting, about the Proxy Statement or about the virtual Annual Meeting, or if you would like additional copies of this Proxy Statement or if you need assistance voting your shares, please contact:

Collectors Universe, Inc.
P. O. Box 6280
Newport Beach, California 92658
Attention: Corporate Secretary
or
Call (949) 567-1157

About Collectors Universe

Collectors Universe, Inc. is a leading provider of value-added services to the collectibles markets. The Company authenticates and grades collectible coins, trading cards, event tickets, autographs and memorabilia). The Company also compiles and publishes authoritative information about United States and world coins, collectible trading cards and sports memorabilia and operates its CCE dealer-to-dealer Internet bid-ask market for certified coins and its Expos trade show and conventions business. This information is accessible to collectors and dealers at the Company’s website, http://www.collectorsuniverse.com, and is also published in print. 

Contacts

Shelton Group
Leanne K. Sievers
949-224-3874
[email protected]

MacKenzie Partners, Inc.
Bob Marese
212-929-5405
[email protected]

SAN FRANCISCO, Nov. 24, 2020 (GLOBE NEWSWIRE) — 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced that Rohan Palekar, the company’s Chief Executive Officer, will participate in 1×1 meetings with investors at the Piper Sandler 32nd Annual Virtual Healthcare Conference on Wednesday, December 2, 2020. The conference will take place December 1-3, 2020. An archived webcast of the fireside chat is accessible in the investor section of 89bio’s website.

About 89bio

89bio is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases. The company’s lead product candidate, BIO89-100, is a specifically engineered glycoPEGylated analog of FGF21. BIO89-100 is being developed for the treatment of nonalcoholic steatohepatitis (NASH) and severe hypertriglyceridemia (SHTG). 89bio is headquartered in San Francisco with operations in Herzliya, Israel.

Investor Contact:

Ryan Martins
Chief Financial Officer
[email protected]

Media Contact:

Peter Duckler
773-343-3069
[email protected]

— Groundbreaking; Sustainability; Environmental Upside —

Dallas, TX, Nov. 24, 2020 (GLOBE NEWSWIRE) — via NewMediaWire
 — NaturalShrimp, Inc. (OTCQB: SHMP), the aquaculture Company that has developed and patented the first commercially operational RAS (Recirculating Aquaculture System) for shrimp, announced today that it has finalized a joint venture between NaturalShrimp, Inc. and Ecoponex Systems International, LLC. This was announced in a Letter of Intent on October 12, 2020. This joint venture will utilize and combine the growing technology of NaturalShrimp with the Renewable Energy Efficient Farms (“REEF”) technology owned by Ecoponex. 

Ecoponex will maintain a 49% stake in the new company, with NaturalShrimp having a 51% interest. As part of the agreed upon terms of the joint venture, Ecoponex shall provide production facilities with its REEF technology for mutually approved locations based upon the cost and space estimates provided by NaturalShrimp. Additionally, Ecoponex shall contribute funding for the transaction and it shall be the sole responsibility of Ecoponex to arrange financing to fund the design, procurement, construction and startup of each NaturalShrimp growing facility approved by the managers. 

Ecoponex shall also bear responsibility for obtaining all necessary local, state and Federal permits necessary to construct and operate the Facility and to market and sell shrimp. NaturalShrimp will grant a royalty free license to the company to allow its proprietary shrimp growing technology and production benchmarks. NaturalShrimp will also provide any of its personnel as may be necessary to design, construct and commence operations and start-up as well as ongoing operations and marketing of shrimp produced at the facility. Lastly, NaturalShrimp will provide a performance guarantee that each facility will meet the production volumes that have been requested by Ecoponex, based upon the cost and space requirements provided to Ecoponex.

“We have worked diligently towards the close of this groundbreaking relationship between NaturalShrimp and Ecoponex,” said Gerald Easterling, CEO of NaturalShrimp. “We believe our technology platform, coupled with Ecoponex’s revolutionary approach to sustainability, provides us a perfect platform for this partnership.  We will update all stakeholders as we commence this venture,” added Mr. Easterling. 

“We are incredibly excited to have completed this joint venture with Ecoponex,” said William Delgado, CFO of NaturalShrimp. “We feel that their REEF technology combined with the aquaculture technology developed by our Company will provide environmental benefits for the climate and ultimately help us reduce our carbon footprint,” added Mr. Delgado.

“For Ecoponex, this joint venture represents a significant milestone in the evolution of our company that reflects the best-in-class approach we’ve taken to closely collaborate and align ourselves with innovators and leaders in the rapidly growing aquaculture industry like NaturalShrimp,” commented Benjamin Brant, CEO. “Toward this end, we believe NaturalShrimp’s patented growing technology not only offers us distinct competitive advantages in the marketplace for fresh organic seafood, but is a perfect fit for our unique closed-loop REEF process where we develop aquaculture projects designed as truly sustainable and self-reliant net-zero energy, water, waste and carbon operations. This is the ultimate goal of our collaboration that could make us one of the lowest cost, most efficient and profitable producers of preferred consumer products in the high-tech aquaculture and fresh food-tech industry,” Mr. Brant added.

About Ecoponex Systems International, LLC: Ecoponex is a privately held company that is in the business of developing, financing, owning and operating REEF™ facilities to serve urban markets in the United States and world. REEFs utilize an integrated platform of proprietary, licensed, patented and patent-pending technologies designed as an integrated closed-loop process. This process efficiently and profitably produces healthy fresh food and renewable energy while recovering CO2, nutrients and clean water to make it a self-reliant net zero operation. REEFs address local environmental and organic waste problems for the benefit of communities, create new jobs, and offer educational/training opportunities and local sustainable economic development by establishing a circular economy with upcycling and repurposing waste. 

About NaturalShrimp: NaturalShrimp, Inc. is a publicly traded aqua-tech Company, headquartered in Dallas, with production facilities located near San Antonio, Texas. The Company has developed the first commercially viable system for growing shrimp in enclosed, salt-water systems, using patented technology to produce fresh, never frozen, naturally grown shrimp, without the use of antibiotics or toxic chemicals. NaturalShrimp systems can be located anywhere in the world to produce gourmet-grade Pacific white shrimp.

Forward-Looking Statements

This press release contains “forward-looking statements.” The statements contained in this press release that are not purely historical are forward-looking statements. Forward-looking statements give the Company’s current expectations or forecasts of future events. Such statements are subject to risks and uncertainties that are often difficult to predict and beyond the Company’s control and could cause the Company’s results to differ materially from those described. In some cases, forward-looking statements can be identified by terminology such as “may,” “should,” “potential,” “continue,” “expects,” “anticipates,” “intends,” “plans,” “believes,” “estimates,” and similar expressions. These statements include statements regarding moving forward with executing the Company’s global growth strategy.

The statements are based upon current beliefs, expectations, and assumptions and are subject to a number of risks and uncertainties, many of which are difficult to predict. The Company is providing this information as of the date of this press release and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise, except as required by law. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends affecting the financial condition of our business.

Forward-looking statements should not be read as a guarantee of future performance or results and will not necessarily be accurate indications of the times at, or by, which such performance or results will be achieved. Important factors that could cause such differences include but are not limited to the Risk Factors and other information set forth in the Company’s Annual Report on Form 10-K filed on March 30, 2015, and in our other filings with the U.S. Securities and Exchange Commission.

Contact:

Paul Knopick

[email protected]

940.262.3584